The earnings call reflected strong revenue growth and successful global expansion initiatives, with improvements in cost management and financial health. However, the increased net loss, challenges in Assisi sales, and potential delisting risk present concerns moving forward.

Company Guidance

During the Zomedica Q3 2024 earnings call, the company provided guidance indicating strong performance across multiple metrics. Zomedica achieved a record revenue of $7 million, marking over 10% growth compared to Q3 2023 and marking the 14th consecutive quarter of revenue growth. The Therapeutic Devices segment grew by 8.5%, driven by a 24% increase in PulseVet performance, while the Diagnostics segment saw a 38% rise, largely due to an 80% growth in the TRUFORMA platform. The company reported solid gross margins of 72.3% and reduced operating expenses by over $900,000 compared to the previous quarter. Zomedica's strategic initiatives included expanding international market reach, enhancing product lines, and maintaining a strong financial position with $77.8 million in cash and securities, positioning the company for continued growth and progress towards cash flow and GAAP profitability.

Record Q3 Revenue

Zomedica set a new record for third-quarter revenue at $7 million, reflecting over 10% growth over the third quarter of 2023, marking the 14th consecutive quarter of record revenue highs.

Therapeutic Devices and Diagnostics Growth

Total Therapeutic Device revenue increased 8.5% year-over-year, with PulseVet performance increasing 24%. Diagnostics segment revenue grew 38%, driven by an 80% increase in TRUFORMA platform sales.

Global Expansion Initiatives

Zomedica expanded international reach with new distributor partnerships in the Middle East, Egypt, India, Central America, and Europe, supported by CE marking on all products.

Cost Management and Efficiency

Operating expenses were reduced by over $900,000 compared to the previous quarter, with a focus on leveraging existing infrastructure and improving operating efficiency.

Strong Gross Margins

Gross margin for the quarter was 72.3%, exceeding the previous year's 69% and higher than the targeted range.

Cash Position and Financial Health

Zomedica ended the third quarter with $77.8 million in cash and equivalents, with no debt, and showed a declining trend in cash usage.

---

Zomedica Pharmaceuticals (ZOM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ZOM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 09, 2018	2018 (Q2)	- / -0.04	-0.02	-100.00% (-0.02)	―	―
Nov 13, 2018	2018 (Q3)	- / -0.02	-0.02	0.00% (0.00)	―	―
Feb 26, 2019	2018 (Q4)	- / -0.25	―	―	―	―
May 10, 2019	2019 (Q1)	- / -0.12	-0.02	-500.00% (-0.10)	―	―
Aug 08, 2019	2019 (Q2)	- / -0.02	-0.04	50.00% (+0.02)	―	―
Nov 12, 2019	2019 (Q3)	- / -0.03	-0.02	-50.00% (>-0.01)	―	―
Feb 26, 2020	2019 (Q4)	- / -0.03	-0.25	89.60% (+0.22)	―	―
May 11, 2020	2020 (Q1)	- / -0.02	-0.12	83.33% (+0.10)	―	―
Aug 10, 2020	2020 (Q2)	- / -0.02	-0.02	0.00% (0.00)	―	―
Nov 12, 2020	2020 (Q3)	- / -0.01	-0.03	66.67% (+0.02)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

ZOM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 07, 2024	$0.12	$0.12	0.00%
Aug 14, 2024	$0.16	$0.15	-6.25%
May 09, 2024	$0.16	$0.14	-12.50%
Apr 01, 2024	$0.14	$0.14	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---

FAQ

When does Zomedica Pharmaceuticals (ZOM) report earnings?

Zomedica Pharmaceuticals (ZOM) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.

What is Zomedica Pharmaceuticals (ZOM) earnings time?

Zomedica Pharmaceuticals (ZOM) earnings time is at Mar 04, 2025, TBA Not Confirmed.

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ZOM EPS forecast?

ZOM EPS forecast for the fiscal quarter 2024 (Q4) is >-0.01.

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing